Healthcare Industry News: osteoarthritis
News Release - May 10, 2006
Smith & Nephew Receives FDA Approval for BIRMINGHAM HIP(TM) Resurfacing SystemMEMPHIS, Tenn., May 10 (HSMN NewsFeed) -- Smith & Nephew's Orthopaedic Reconstruction division (LSE: SN ; NYSE: SNN ) announced today that the U.S. Food and Drug Administration (FDA) has approved the BIRMINGHAM HIP(TM) Resurfacing system for use in the United States. The BIRMINGHAM HIP Resurfacing system is the only FDA-approved hip resurfacing system available for use in the U.S.
Hip resurfacing is an alternative to total hip replacement for patients suffering from abnormalities of the hip, including osteoarthritis.
The BIRMINGHAM HIP Resurfacing system conserves more of a patient's bone than a traditional hip replacement, enabling younger, more active patients to undergo hip replacement surgery while preserving all future surgery options, including a primary hip replacement. The design of The BIRMINGHAM HIP Resurfacing system also offers patients a better range of natural motion with a reduced risk of dislocation.
Developed by Surgeons Derek McMinn and Ronan Treacy, BIRMINGHAM HIP Resurfacing system was first introduced in July 1997 in the UK and has now been implanted in more than 60,000 patients in 26 countries.
"The BIRMINGHAM HIP Resurfacing system offers younger, more active patients a stable implant that enables them to regain and maintain their active lifestyle after surgery," said Scott Flora, president of Smith & Nephew Orthopaedic Reconstruction. "The long-term clinical data available demonstrates the benefits of the BIRMINGHAM HIP Resurfacing system, which is the premier hip resurfacing technology in the world and a significant addition to our reconstructive product portfolio in the United States. The addition of BIRMINGHAM HIP Resurfacing system as the only FDA-approved hip resurfacing technology gives Smith & Nephew the broadest and most comprehensive product range of advanced bearing surfaces for the hip."
Smith & Nephew will be training 50 surgeons in the first phase of the U.S. introduction. Training will be provided in the United States and Europe, with the first U.S. surgeries expected to take place this summer.
For more information on the BIRMINGHAM HIP Resurfacing system, visit www.birminghamhipresurfacing.com.
Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the fastest growing global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has over 8,500 employees and operates in 33 countries around the world generating annual sales of $2.6 billion in 2005.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward- looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
* Trademark of Smith & Nephew. Certain names registered at the US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew Announces US Launch of Pico(TM) 14 Single Use Negative Pressure Wound Therapy System for Use On High Risk Surgical Patients
New study shows 96% healing of hard to treat large and massive rotator cuff tears with Smith & Nephew's REGENETEN(TM) Bioinductive Implant
Smith & Nephew launches industry-first OR3O(TM) Dual Mobility System utilizing unique OXINIUM(TM) DH metal alloy for use in primary and revision hip arthroplasty